Role of C-Reactive Protein, An Inflammatory Biomarker in The Development of Atherosclerosis and Its Treatment

Abstract

This article deals with the role of c-reactive protein (CRP) in the development of atherosclerosis and its treatment. CRP has a predictive value in ischemic heart disease, restenosis, coronary artery disease, aortic atherosclerosis, and cerebrovascular disease. This article deals with the synthesis and mechanism of CRP-induced atherosclerosis and its treatment. CRP increases the formation of numerous atherogenic biomolecules such as reactive oxygen species (ROS), cytokines (interleukin [IL]-1β and IL-6), cell adhesion molecules (intercellular adhesion molecule-1, vascular cell adhesion molecule-1, monocyte chemoattractant protein-1, activated complement C₅, monocyte colony-stimulating factor, and numerous growth factors [insulin-like growth factor, platelet-derived growth factor, and transforming growth factor-β]). ROS mildly oxidizes low-density lipoprotein (LDL)-cholesterol to form minimally modified LDL which is further oxidized to form oxidized LDL. The above atherogenic biomolecules are involved in the development of atherosclerosis and has been described in detail in the text. This paper also deals with the treatment modalities for CRP-induced atherosclerosis which includes lipid-lowering drugs, antihypertensive drugs, antioxidants, aspirin, antidiabetic drugs, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, regular physical activity, weight reduction, and stoppage of cigarette smoking. In conclusion, CRP induces atherosclerosis through increases in atherogenic biomolecules and the treatment modalities would prevent, regress, and slow the progression of CRP-induced atherosclerosis.

Keywords

C-reactive protein - atherosclerosis - synthesis of CRP - functions of CRP - atherogenic biomolecules - cardiovascular disease - CRP lowering agents - physical activity - weight reduction - stoppage of cigarette smoking

Publication History

Article published online:
18 July 2024

• References

• 1 Prasad K, Mishra M. Mechanism of hypercholesterolemia-induced atherosclerosis. Rev Cardiovasc Med 2022; 23 (06) 212
• 2 Summerhill VI, Grechko AV, Yet SF. et al. The atherogenic role of circulating modified lipids in atherosclerosis. Int J Mol Sci 2019; 20 (14) 1-14
• 3 Ross R, Harker L. Hyperlipidemia and atherosclerosis. Science 1976; 193 (4258) 1094-1100
• 4 Swastini DA, Wiryanthini IAD, Ariastuti NLP, Muliantara A. Atherosclerosis prediction with high sensitivity C-reactive protein (hs-CRP) and related risk factor in patient with dyslipidemia. Open Access Maced J Med Sci 2019; 7 (22) 3887-3890
• 5 Mai W, Liao Y. Targeting IL-1β in the treatment of atherosclerosis. Front Immunol 2020; 11: 589654
• 6 Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101 (15) 1767-1772
• 7 Bruunsgaard H, Skinhøj P, Pedersen AN, Schroll M, Pedersen BK. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol 2000; 121 (02) 255-260
• 8 Prasad K. C-reactive protein and cardiovascular diseases. Int J Angiol 2003; 12: 1-12
• 9 Karadag F, Kirdar S, Karul AB, Ceylan E. The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease. Eur J Intern Med 2008; 19 (02) 104-108
• 10 Cederström S, Lundman P, Alfredsson J. et al. Association between high-sensitivity C-reactive protein and coronary atherosclerosis in a general middle-aged population. Sci Rep 2023; 13 (01) 12171
• 11 Shrivastava AK, Singh HV, Raizada A, Singh SK. C-reactive protein, inflammation and coronary heart disease. Egypt Heart J 2015; 67: 89-97
• 12 Ridker PM, Rifai N, Pfeffer MA. et al; Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98 (09) 839-844
• 13 Osman R, L'Allier PL, Elgharib N, Tardif JC. Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. Vasc Health Risk Manag 2006; 2 (03) 221-237
• 14 Biasucci LM, Liuzzo G, Colizzi C, Rizzello V. Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease. Ital Heart J 2001; 2 (03) 164-171
• 15 Shankar A, Li J, Nieto FJ, Klein BEK, Klein R. Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. Am Heart J 2007; 154 (03) 495-501
• 16 Van Der Meer IM, De Maat MP, Hak AE. et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: the Rotterdam Study. Stroke 2002; 33 (12) 2750-2755
• 17 Di Napoli M, Elkind MSV, Godoy DA, Singh P, Papa F, Popa-Wagner A. Role of C-reactive protein in cerebrovascular disease: a critical review. Expert Rev Cardiovasc Ther 2011; 9 (12) 1565-1584
• 18 Agmon Y, Khandheria BK, Meissner I. et al. C-reactive protein and atherosclerosis of the thoracic aorta: a population-based transesophageal echocardiographic study. Arch Intern Med 2004; 164 (16) 1781-1787
• 19 Morrow DA, Ridker PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am 2000; 84 (01) 149-161 , ix
• 20 Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285 (19) 2481-2485
• 21 Ridker PMJ, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342 (12) 836-843
• 22 Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol 2018; 9: 754
• 23 Szalai AJ, van Ginkel FW, Dalrymple SA, Murray R, McGhee JR, Volanakis JE. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J Immunol 1998; 160 (11) 5294-5299
• 24 Ngwa DN, Pathak A, Agrawal A. IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms. Mol Immunol 2022; 146: 50-56
• 25 Wigmore SJ, Fearon KC, Maingay JP, Lai PB, Ross JA. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol 1997; 273 (04) E720-E726
• 26 Calabró P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108 (16) 1930-1932
• 27 Hage FG, Szalai AJ. C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 2007; 50 (12) 1115-1122
• 28 Pankow JS, Folsom AR, Cushman M. et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001; 154 (03) 681-689
• 29 Kurtz EG, Ridker PM, Rose LM. et al. Oral postmenopausal hormone therapy, C-reactive protein, and cardiovascular outcomes. Menopause 2011; 18 (01) 23-29
• 30 Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100 (07) 713-716
• 31 Lacut K, Oger E, Le Gal G. et al; SARAH Investigators. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost 2003; 90 (01) 124-131
• 32 Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 2003; 41 (08) 1358-1363
• 33 Casanova G, dos Reis AM, Spritzer PM. Low-dose oral or non-oral hormone therapy: effects on C-reactive protein and atrial natriuretic peptide in menopause. Climacteric 2015; 18 (01) 86-93
• 34 Verhamme P, Quarck R, Hao H. et al. Dietary cholesterol withdrawal reduces vascular inflammation and induces coronary plaque stabilization in miniature pigs. Cardiovasc Res 2002; 56 (01) 135-144
• 35 Tannock LR, O'Brien KD, Knopp RH. et al. Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation 2005; 111 (23) 3058-3062
• 36 Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103 (09) 1191-1193
• 37 Bismuth J, Kofoed SC, Jensen AS, Sethi A, Sillesen H. Serum lipids act as inverse acute phase reactants and are falsely low in patients with critical limb ischemia. J Vasc Surg 2002; 36 (05) 1005-1010
• 38 Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension 2002; 39 (03) 777-780
• 39 Gessler P, Nebe T, Birle A, Haas N, Kachel W. Neutrophil respiratory burst in term and preterm neonates without signs of infection and in those with increased levels of C-reactive protein. Pediatr Res 1996; 39 (05) 843-848
• 40 Prasad K. C-reactive protein increases oxygen radical generation by neutrophils. J Cardiovasc Pharmacol Ther 2004; 9 (03) 203-209
• 41 Kawanami D, Maemura K, Takeda N. et al. C-reactive protein induces VCAM-1 gene expression through NF-kappa B activation in vascular endothelial cells. Atherosclerosis 2006; 185 (01) 39-46
• 42 Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102 (18) 2165-2168
• 43 Blann AD, Lip GY. Effects of C-reactive protein on the release of von Willebrand factor, E-selectin, thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells. Blood Coagul Fibrinolysis 2003; 14 (04) 335-340
• 44 Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999; 42 (1-3): 23-30
• 45 Wezel A, de Vries MR, Lagraauw HM. et al. Complement factor C5a induces atherosclerotic plaque disruptions. J Cell Mol Med 2014; 18 (10) 2020-2030
• 46 Selle J, Asare Y, Köhncke J. et al. Atheroprotective role of C5ar2 deficiency in apolipoprotein E-deficient mice. Thromb Haemost 2015; 114 (04) 848-858
• 47 Kiss MG, Binder CJ. The multifaceted impact of complement on atherosclerosis. Atherosclerosis 2022; 351: 29-40
• 48 Pasceri V, Cheng JS, Willerson JT, Yeh ETH. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103 (21) 2531-2534
• 49 Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Nerem RM. The pathogenesis of atherosclerosis: an overview. Clin Cardiol 1991; 14 (2, suppl 1): I1-I16
• 50 Jiang Y, Beller DI, Frendl G, Graves DT. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J Immunol 1992; 148 (08) 2423-2428
• 51 Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996; 271 (30) 17779-17784
• 52 Yamaguchi Y, Matsumura F, Takeya M. et al. Monocyte chemoattractant protein-1 enhances expression of intercellular adhesion molecule-1 following ischemia-reperfusion of the liver in rats. Hepatology 1998; 27 (03) 727-734
• 53 Kibayashi E, Urakaze M, Kobashi C. et al. Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells. Clin Sci (Lond) 2005; 108 (06) 515-521
• 54 Han KH, Hong KH, Park JH. et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004; 109 (21) 2566-2571
• 55 Verma S, Wang CH, Li SH. et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106 (08) 913-919
• 56 Eisenhardt SU, Thiele JR, Bannasch H, Stark GB, Peter K. C-reactive protein: how conformational changes influence inflammatory properties. Cell Cycle 2009; 8 (23) 3885-3892
• 57 Devaraj S, Venugopal S, Jialal I. Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein. Atherosclerosis 2006; 184 (01) 48-52
• 58 Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106 (12) 1439-1441
• 59 Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29 (06) 313-326
• 60 Hofmann MA, Drury S, Fu C. et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97 (07) 889-901
• 61 Su CM, Wang L, Yoo D. Activation of NF-κB and induction of proinflammatory cytokine expressions mediated by ORF7a protein of SARS-CoV-2. Sci Rep 2021; 11 (01) 13464
• 62 Pignol B, Hénane S, Mencia-Huerta JM, Rola-Pleszczynski M, Braquet P. Effect of platelet-activating factor (PAF-acether) and its specific receptor antagonist, BN 52021, on interleukin 1 (IL1) release and synthesis by rat spleen adherent monocytes. Prostaglandins 1987; 33 (06) 931-939
• 63 Bonavida B, Mencia-Huerta JM, Braquet P. Effect of platelet-activating factor on monocyte activation and production of tumor necrosis factor. Int Arch Allergy Appl Immunol 1989; 88 (1-2): 157-160
• 64 Basta G, Del Turco S, Marchi F. et al. Elevated soluble receptor for advanced glycation end product levels in patients with acute coronary syndrome and positive cardiac troponin I. Coron Artery Dis 2011; 22 (08) 590-594
• 65 Meager A. Cytokine regulation of cellular adhesion molecule expression in inflammation. Cytokine Growth Factor Rev 1999; 10 (01) 27-39
• 66 Chiu JJ, Wung BS, Shyy JY, Hsieh HJ, Wang DL. Reactive oxygen species are involved in shear stress-induced intercellular adhesion molecule-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17 (12) 3570-3577
• 67 Sellak H, Franzini E, Hakim J, Pasquier C. Reactive oxygen species rapidly increase endothelial ICAM-1 ability to bind neutrophils without detectable upregulation. Blood 1994; 83 (09) 2669-2677
• 68 Cook-Mills JM, Marchese ME, Abdala-Valencia H. Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants. Antioxid Redox Signal 2011; 15 (06) 1607-1638
• 69 Kim SR, Bae YH, Bae SK. et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 2008; 1783 (05) 886-895
• 70 Rahman A, Kefer J, Bando M, Niles WD, Malik AB. E-selectin expression in human endothelial cells by TNF-alpha-induced oxidant generation and NF-kappaB activation. Am J Physiol 1998; 275 (03) L533-L544
• 71 Delafontaine P, Ku L. Reactive oxygen species stimulate insulin-like growth factor I synthesis in vascular smooth muscle cells. Cardiovasc Res 1997; 33 (01) 216-222
• 72 Chung J, Huda MN, Shin Y. et al. Correlation between oxidative stress and transforming growth factor-beta in cancers. Int J Mol Sci 2021; 22 (24) 13181
• 73 Lee P, Prasad K. Effects of flaxseed oil on serum lipids and atherosclerosis in hypercholesterolemic rabbits. J Cardiovasc Pharmacol Ther 2003; 8 (03) 227-235
• 74 Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am Heart J 1993; 125 (04) 958-973
• 75 Steinberg D. Antioxidants in the prevention of human atherosclerosis. Summary of the proceedings of a National Heart, Lung, and Blood Institute Workshop: September 5-6, 1991, Bethesda, Maryland. Circulation 1992; 85 (06) 2337-2344
• 76 Prasad K, Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis 2007; 192 (02) 313-322
• 77 Parthasarathy S, Raghavamenon A, Garelnabi MO, Santanam N. Oxidized low-density lipoprotein. Methods Mol Biol 2010; 610: 403-417
• 78 Poznyak AV, Nikiforov NG, Markin AM. et al. Overview of OxLDL and its impact on cardiovascular health: focus on atherosclerosis. Front Pharmacol 2021; 11: 613780
• 79 Hashimoto K, Kataoka N, Nakamura E, Tsujioka K, Kajiya F. Oxidized LDL specifically promotes the initiation of monocyte invasion during transendothelial migration with upregulated PECAM-1 and downregulated VE-cadherin on endothelial junctions. Atherosclerosis 2007; 194 (02) e9-e17
• 80 Prasad K. Pathophysiology of atherosclerosis. Textbook of Angiology. 2000; 295: 85-105
• 81 Reale M, Di Giulio C, Cacchio M. et al. Oxygen supply modulates MCP-1 release in monocytes from young and aged rats: decrease of MCP-1 transcription and translation is age-related. Mol Cell Biochem 2003; 248 (1-2): 1-6
• 82 Harrington JR. The role of MCP-1 in atherosclerosis. Stem Cells 2000; 18 (01) 65-66
• 83 Zeller JM, Sullivan BL. C-reactive protein selectively enhances the intracellular generation of reactive oxygen products by IgG-stimulated monocytes and neutrophils. J Leukoc Biol 1992; 52 (04) 449-455
• 84 Li H, Cybulsky MI, Gimbrone Jr MA, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993; 13 (02) 197-204
• 85 Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002; 1: 1-10
• 86 Cushing SD, Berliner JA, Valente AJ. et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 1990; 87 (13) 5134-5138
• 87 Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 1997; 8 (10) 1537-1545
• 88 Obermayer G, Afonyushkin T, Binder CJ. Oxidized low-density lipoprotein in inflammation-driven thrombosis. J Thromb Haemost 2018; 16 (03) 418-428
• 89 Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 1979; 76 (01) 333-337
• 90 Leiva E, Wehinger S, Guzmán L, Orrego R. Role of oxidized LDL in Atherosclerosis. Hypercholesterolemia. InTech; 2015. . Accessed June 25, 2024 at: http://dx.doi.org/10.5772/59375
• 91 Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272 (34) 20963-20966
• 92 Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis 1983; 3 (02) 149-159
• 93 Klinkner AM, Waites CR, Kerns WD, Bugelski PJ. Evidence of foam cell and cholesterol crystal formation in macrophages incubated with oxidized LDL by fluorescence and electron microscopy. J Histochem Cytochem 1995; 43 (10) 1071-1078
• 94 Fu Y, Wu Y, Liu E. C-reactive protein and cardiovascular disease: from animal studies to the clinic (Review). Exp Ther Med 2020; 20 (02) 1211-1219
• 95 Paul A, Ko KW, Li L. et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109 (05) 647-655
• 96 Schwedler SB, Amann K, Wernicke K. et al. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 2005; 112 (07) 1016-1023
• 97 Zebrack JS, Muhlestein JB, Horne BD, Anderson JL. Intermountain Heart Collaboration Study Group. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol 2002; 39 (04) 632-637
• 98 Kirkgöz K. C-reactive protein in atherosclerosis—more than a biomarker, but not just a culprit. Rev Cardiovasc Med 2023; 24 (10) 297
• 99 Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 2001; 32 (01) 133-138
• 100 Masotti L, Ceccarelli E, Forconi S, Cappelli R. Prognostic role of C-reactive protein in very old patients with acute ischaemic stroke. J Intern Med 2005; 258 (02) 145-152
• 101 Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24 (01) 33-50
• 102 Wang CY, Chang TC. Non-HDL cholesterol level is reliable to be an early predictor for vascular inflammation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89 (09) 4762-4767
• 103 Kandelouei T, Abbasifard M, Imani D. et al. Effect of statins on serum level of hs-CRP and CRP in patients with cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials. Mediators Inflamm 2022; 2022: 8732360
• 104 Plenge JK, Hernandez TL, Weil KM. et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002; 106 (12) 1447-1452
• 105 Nissen SE, Tuzcu EM, Schoenhagen P. et al; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352 (01) 29-38
• 106 Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. The Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100 (03) 230-235
• 107 Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 2003; 169 (01) 155-158
• 108 Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999; 353 (9147) 118-119
• 109 Li JJ, Chen MZ, Chen X, Fang CH. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol 2003; 26 (10) 472-476
• 110 Chou R, Cantor A, Dana T. et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2022; 328 (08) 754-771
• 111 Ridker PM, Danielson E, Fonseca FA. et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359 (21) 2195-2207
• 112 Arnaud C, Burger F, Steffens S. et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 2005; 25 (06) 1231-1236
• 113 Tamarappoo B, Otaki Y, Doris M. et al. Improvement in LDL is associated with decrease in non-calcified plaque volume on coronary CTA as measured by automated quantitative software. J Cardiovasc Comput Tomogr 2018; 12 (05) 385-390
• 114 Lee S-E, Chang H-J, Sung JM. et al. Effects of statins on coronary atherosclerotic plaques: the PARADIGM study. JACC Cardiovasc Imaging 2018; 11 (10) 1475-1484
• 115 Ballantyne CM, Houri J, Notarbartolo A. et al; Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107 (19) 2409-2415
• 116 Gagné C, Bays HE, Weiss SR. et al; Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90 (10) 1084-1091
• 117 Coban E, Sari R. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients. Endocr Res 2004; 30 (03) 343-349
• 118 Yesilbursa D, Serdar A, Saltan Y. et al. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia. Kardiol Pol 2005; 62 (06) 526-530
• 119 Kim CJ. Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients. J Cardiovasc Pharmacol 2006; 47 (06) 758-763
• 120 Jenkins DJ, Kendall CW, Marchie A. et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290 (04) 502-510
• 121 Bautista LE, Atwood JE, O'Malley PG, Taylor AJ. Association between C-reactive protein and hypertension in healthy middle-aged men and women. Coron Artery Dis 2004; 15 (06) 331-336
• 122 Palmas W, Ma S, Psaty B, Goff Jr DC, Darwin C, Barr RG. Antihypertensive medications and C-reactive protein in the multi-ethnic study of atherosclerosis. Am J Hypertens 2007; 20 (03) 233-241
• 123 Jenkins NP, Keevil BG, Hutchinson IV, Brooks NH. Beta-blockers are associated with lower C-reactive protein concentrations in patients with coronary artery disease. Am J Med 2002; 112 (04) 269-274
• 124 Anzai T, Yoshikawa T, Takahashi T. et al. Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology 2003; 99 (01) 47-53
• 125 Joynt KE, Gattis WA, Hasselblad V. et al. Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol 2004; 93 (06) 783-785
• 126 Pahor M, Franse LV, Deitcher SR. et al. Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. Circulation 2002; 105 (04) 457-461
• 127 Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 2004; 43 (11) 2116-2123
• 128 Asbaghi O, Sadeghian M, Nazarian B. et al. The effect of vitamin E supplementation on selected inflammatory biomarkers in adults: a systematic review and meta-analysis of randomized clinical trials. Sci Rep 2020; 10 (01) 17234
• 129 Saboori S, Shab-Bidar S, Speakman JR, Yousefi Rad E, Djafarian K. . Effect of vitamin E supplementation on serum C-reactive protein level: a meta-analysis of randomized controlled trial. Eur J Clin Nutr 2015; 69 (08) 867-873
• 130 Murphy RT, Foley JB, Tome MT. et al. Vitamin E modulation of C-reactive protein in smokers with acute coronary syndromes. Free Radic Biol Med 2004; 36 (08) 959-965
• 131 Upritchard JE, Sutherland WH, Mann JI. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care 2000; 23 (06) 733-738
• 132 Ding N, Zeng Z, Luo J, Li K. The cross-sectional relationship between vitamin C and high-sensitivity C-reactive protein levels: insights from NHANES database. Front Nutr 2023; 10: 1290749
• 133 Langlois M, Duprez D, Delanghe J, De Buyzere M, Clement DL. Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 2001; 103 (14) 1863-1868
• 134 Sánchez-Moreno C, Dashe JF, Scott T, Thaler D, Folstein MF, Martin A. Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. Stroke 2004; 35 (01) 163-168
• 135 Julia C, Galan P, Touvier M. et al. Antioxidant status and the risk of elevated C-reactive protein 12 years later. Ann Nutr Metab 2014; 65 (04) 289-298
• 136 Fujii H, Li SH, Szmitko PE, Fedak PW, Verma S. C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2006; 26 (11) 2476-2482
• 137 Kubota Y, Moriyama Y, Yamagishi K. et al. Serum vitamin C concentration and hs-CRP level in middle-aged Japanese men and women. Atherosclerosis 2010; 208 (02) 496-500
• 138 Gebreselassie SG, Gase FE, Deressa MU. Prevalence and correlates of prenatal vitamin A deficiency in rural Sidama, Southern Ethiopia. J Health Popul Nutr 2013; 31 (02) 185-194
• 139 Lee H, Kim KN, Lim YH, Hong YC. Interaction of vitamin D and smoking on inflammatory markers in the urban elderly. J Prev Med Public Health 2015; 48 (05) 249-256
• 140 Pandey S, Garg R, Kant S, Gaur P. Vitamin D, C-reactive protein, and oxidative stress markers in chronic obstructive pulmonary disease. Tzu-Chi Med J 2019; 33 (01) 80-86
• 141 Feldman M, Jialal I, Devaraj S, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol 2001; 37 (08) 2036-2041
• 142 Kennon S, Price CP, Mills PG. et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol 2001; 37 (05) 1266-1270
• 143 Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100 (08) 793-798
• 144 Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM. CADET Study Investigators. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost 2004; 2 (11) 1934-1940
• 145 Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106 (06) 679-684
• 146 Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26 (01) 172-178
• 147 Ridker PM, Cannon CP, Morrow D. et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352 (01) 20-28
• 148 Hussain M, Rafique MA, Iqbal J, Akhtar L. Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients. Pak J Med Sci 2019; 35 (02) 383-387
• 149 Katsiki N, Ferrannini E. Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?. J Diabetes Complications 2020; 34 (12) 107723
• 150 Mitrovic V, Klein HH, Krekel N. et al. Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis. Z Kardiol 2005; 94 (05) 336-342
• 151 Ateya AM, El Hakim I, Shahin SM, El Borolossy R, Kreutz R, Sabri NA. Effects of ramipril on biomarkers of endothelial dysfunction and inflammation in hypertensive children on maintenance hemodialysis: the SEARCH randomized placebo-controlled trial. Hypertension 2022; 79 (08) 1856-1865
• 152 Lonn E, Yusuf S, Dzavik V. et al; SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103 (07) 919-925
• 153 Tsikouris JP, Suarez JA, Simoni JS, Ziska M, Meyerrose GE. Exploring the effects of ACE inhibitor tissue penetration on vascular inflammation following acute myocardial infarction. Coron Artery Dis 2004; 15 (04) 211-217
• 154 Oubiña MP, de las Heras N, Cediel E. et al. Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits. Clin Sci (Lond) 2003; 105 (06) 655-662
• 155 Berezin AE. [Effect of fosinopril on the rate of neurohumoral and proinflammatory activation in patients with heart failure]. Klin Med (Mosk) 2004; 82 (09) 29-32
• 156 Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005; 27 (05) 578-587
• 157 Dandona P, Kumar V, Aljada A. et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003; 88 (09) 4496-4501
• 158 Derosa G, Maffioli P, Salvadeo SA. et al. Candesartan effect on inflammation in hypertension. Hypertens Res 2010; 33 (03) 209-213
• 159 Sakamoto M, Suzuki H, Hayashi T. et al. Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure. Cardiovasc Diabetol 2012; 11: 118
• 160 Schieffer B, Bünte C, Witte J. et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004; 44 (02) 362-368
• 161 Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology 2002; 13 (05) 561-568
• 162 Reuben DB, Judd-Hamilton L, Harris TB, Seeman TE. MacArthur Studies of Successful Aging. The associations between physical activity and inflammatory markers in high-functioning older persons: MacArthur studies of successful aging. J Am Geriatr Soc 2003; 51 (08) 1125-1130
• 163 Esteghamati A, Morteza A, Khalilzadeh O. et al. Physical inactivity is correlated with levels of quantitative C-reactive protein in serum, independent of obesity: results of the national surveillance of risk factors of non-communicable diseases in Iran. J Health Popul Nutr 2012; 30 (01) 66-72
• 164 Mendham AE, Duffield R, Marino F, Coutts AJ. Small-sided games training reduces CRP, IL-6 and leptin in sedentary, middle-aged men. Eur J Appl Physiol 2014; 114 (11) 2289-2297
• 165 Beavers KM, Beavers DP, Newman JJ. et al. Effects of total and regional fat loss on plasma CRP and IL-6 in overweight and obese, older adults with knee osteoarthritis. Osteoarthritis Cartilage 2015; 23 (02) 249-256
• 166 Kuczmarski MF, Mason MA, Allegro D, Zonderman AB, Evans MK. Diet quality is inversely associated with C-reactive protein levels in urban, low-income African-American and white adults. J Acad Nutr Diet 2013; 113 (12) 1620-1631
• 167 O'Brien KD, Brehm BJ, Seeley RJ. et al. Diet-induced weight loss is associated with decreases in plasma serum amyloid a and C-reactive protein independent of dietary macronutrient composition in obese subjects. J Clin Endocrinol Metab 2005; 90 (04) 2244-2249
• 168 Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003; 138 (11) 891-897
• 169 Stewart SH, Mainous III AG, Gilbert G. Relation between alcohol consumption and C-reactive protein levels in the adult US population. J Am Board Fam Pract 2002; 15 (06) 437-442
• 170 Stanimirovic J, Radovanovic J, Banjac K. et al. Role of C-reactive protein in diabetic inflammation. Mediators Inflamm 2022; 2022: 3706508
• 171 Kanmani S, Kwon M, Shin MK, Kim MK. Association of C-reactive protein with risk of developing type 2 diabetes mellitus, and role of obesity and hypertension: a large population-based Korean cohort study. Sci Rep 2019; 9 (01) 4573
• 172 Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean MEJ, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 25 (11) 2016-2021
• 173 Kato K, Otsuka T, Saiki Y. et al. Association between elevated c-reactive protein levels and prediabetes in adults, particularly impaired glucose tolerance. Can J Diabetes 2019; 43 (01) 40-45.e2
• 174 Prasad K. Involvement of AGE and its receptors in the pathogenesis of hypertension in elderly people and its treatment. Int J Angiol 2022; 31 (04) 213-221
• 175 Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992; 23: 1-34
• 176 Prasad K. AGE-RAGE stress in the pathophysiology of atherosclerosis and its treatment. In: Sobti RC, Ganju AK. eds. Biomedical Translational Research. From Disease Diagnosis To Treatment. Switzerland AG: Springer Nature; 2022: 1-11
• 177 Montecucco F, Mach F. New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. Clin Interv Aging 2008; 3 (02) 341-349
• 178 Danesh J, Whincup P, Walker M. et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321 (7255) 199-204
• 179 Danesh J, Wheeler JG, Hirschfield GM. et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350 (14) 1387-1397
• 180 Park R, Detrano R, Xiang M. et al. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation 2002; 106 (16) 2073-2077